DaVita Q2 FY26 operating income climbs 20.1% to $579 million; revenue rises 4% to $3.55 billion
DVA•Integrated kidney care
Integrated kidney care swung to Q2 operating income of $40 million on higher shared savings; plans to roll out expanded HD broadly.
Q2 and six-month results
DaVita Q2 2026 operating income rose 20.1% to $579 million as revenue climbed 4% to $3.55 billion.
Six-month net income increased 21.9% to $618 million as operating income rose 8.6% to $1.06 billion.
U.S. dialysis performance
U.S. dialysis Q2 revenue rose 2.4% to $3.01 billion while treatments increased 2.8% to 7,226,600.
U.S. dialysis patient service revenue per treatment slipped 0.4% to $415.87; patient care costs per treatment fell 1% to $277.40.
